GSK sells Chinese Tykerb rights to Eddingpharm; Novartis cuts 120 jobs in Fort Worth;

@FiercePharma: Trending yesterday: U.S. adults still skipping pills to save money, CDC finds. Article | Follow @FiercePharma

@EricPFierce: Drugmakers with plants in EU still sweating whether China, India will meet deadline for new API regulations. Report | Follow @EricPFierce

> GlaxoSmithKline ($GSK) licensed the Chinese rights to its breast cancer treatment Tykerb to Eddingpharm, which will import and sell the drug in the country. Report

> Novartis ($NVS) laid off 120 Alcon employees in Fort Worth, TX, with plans to move the jobs to Cambridge, MA; the Texas employees can apply for jobs in Cambridge or elsewhere within Alcon. Report

> Apotex did not initially warn women of packaging problems with its Alysena birth controll pill but issued a retailer-level recall; Health Canada upgraded the recall this week to require that patients be notified. Report

> GW Pharmaceuticals said its cannabis-based medicine Sativex was moved to a less-restrictive category on the U.K. drug schedule. Report

> General Electric ($GE) and iBio ($IBIO) won a contract to design a vaccine-manufacturing plant in Brazil. Report

Medical Device News

@FierceMedDev: Report: Device tax is hard to decipher and kills jobs. More | Follow @FierceMedDev

@MarkHFierce: Med device VC continues to be steady for late stage companies. iRhythm pulled in a $16M Series D. Release | Follow @MarkHFierce

 @DamianFierce: St. Jude won EU approval to treat dystonia with its deep-brain simulators. News | Follow @DamianFierce

> Abbott/BG heart failure Dx gains CE mark. More

> Smiths Medical faces FDA Class I recall over sleep alarm cables. Item

> Covidien plans to slash 183 jobs in NY plant closure. Report

Biotech News

@FierceBiotech: Trending: Groton throws up a new hurdle to Pfizer's R&D demolition plan. Story | Follow @FierceBiotech

@JohnCFierce: Fun list from Evaluate on the top 10 blockbuster busts in biopharma. List | Follow @JohnCFierce.

@RyanMFierce: Started my day 2 here at BioIT13 with a story about Novartis' big decision on whether to buy Proteon in $550M deal. News | Follow @RyanMFierce

> VistaGen raises $36M for stem cell tech. More

> Amid cheers and jeers, GlaxoSmithKline reveals Duchenne drug hit primary PhII goal. Article

> FDA stokes blockbuster hopes with 'breakthrough' brand for Pfizer cancer drug. News

Drug Delivery News

@MichaelGFierce: From SpringLeaf's ashes, scPharma continues with minipump delivery. Article | Follow @MichaelGFierce

> TissueGen launches Elute drug-delivering fiber. News

> 3-D printer makes synthetic tissue for drug delivery. Report

> Self-assembling cancer drugs deliver themselves. Item

> Ambrx's cancer antibody delivery tech wins Astellas partnership. More

> Nano-delivered cell gatekeepers can improve drug performance, study finds. Story

And Finally... Scientists are making progress toward an "artificial pancreas" for diabetics. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.